• Assessing Health-related Quality of Life in Sarcoma Patients

  NCT04071704

  CompletedObservationalUpdated Apr 22, 2026
• Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK

  NCT04181970

  RecruitingObservationalUpdated Mar 21, 2025
• Burden and Medical Care of Sarcoma in Germany

  NCT03521531

  CompletedObservationalUpdated Aug 27, 2021
• This is a Randomized Study of Early Involvement of Palliative Care Along Side Standard Treatment Versus Standard Treatment Alone in Newly Diagnosed Patients With Advanced or Metastatic Soft Tissue Sarcoma (SARQUALITY)

  NCT06805669

  RecruitingInterventionalNot ApplicableUpdated Feb 3, 2025
• Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)

  NCT07148193

  RecruitingObservationalUpdated Dec 8, 2025
• Registration Study Sarcoma

  NCT05373810

  RecruitingObservationalUpdated May 23, 2022

ClinicalTrials.gov ID

NCT03441906

Lead Sponsor

Radboud University Medical CenterOTHER

Overall Status

Unknown status

Study Type

Observational

Enrollment

350Estimated

Last Update Posted

Mar 13, 2020Actual

Start Date

Feb 15, 2018Actual

Primary Completion Date

Sep 2020Estimated

Completion Date

Feb 2021Estimated

Official Title

QUEST: QUality of Life and Experiences of Sarcoma Trajectories

Brief Summary

Background:

The prognosis of patients with rare cancers in general and sarcomas in particular suffers from delay in diagnosis. Routes to diagnosis for sarcoma need to be quicker and more streamlined, but have neither been studied in detail in larger numbers before, nor in a direct comparison between two countries with different health systems. Comprehensive assessment of diagnostic delays and its determinants, including demographic, clinical, psychosocial and health care system factors, is necessary to improve referral pathways and come to best practice and patient reported outcomes for sarcoma patients.

Research questions to be answered:

This study aims to quantify diagnostic delay (including patient, general practitioner and system delay) and evaluates routes to diagnosis and referral to sarcoma expert centres in the Netherlands and England; to comprehensively evaluate risk factors of diagnostic delay; determine the association between diagnostic delay and outcomes (health-related quality of life, quality-adjusted life years, patient satisfaction, TNM classification, time to local/distant relapse and overall survival); and to assess differences between both countries. This should lead to advices about faster referral where possible.

Detailed Description

The researchers will conduct a longitudinal cohort study among all sarcoma patients (≥18 years of age) that will be newly diagnosed in 1.5 years period from October 1st 2017 to March 30st 2019 in one of the participating study centers (5 centers in The Netherlands, 3 centers in England).

Patients will be invited before the start of treatment (with a two months eligibility window) and receive a questionnaire on diagnostic delay, risk factors and patient-reported outcomes. The questionnaire on patient-reported outcomes will be completed again 3 months, 6 months, 1-year and 2 years later.

Data collection will be done within PROFILES, an international registry for cancer patient reported outcomes (www.profilesregistry.nl). Clinical data will be collected through cancer registries and the junior investigator will collect extra data from patients' records.

• Quality of Life
• Sarcoma
• Diagnostic Interval
• Diagnostic Pathway
• Care Needs

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age at diagnosis ≥ 18 years
• Diagnosis of sarcoma (histology confirmed by sarcoma histopathologist; according to ICD-10-GM codes C40 and C41 for bone sarcoma and C49 for soft-tissue sarcoma)
• Able to communicate in English (or Dutch)
• Mental capacity to provide informed consent and to participate in the study (as determined by the referring health care professional)
• Patients must be able to complete questionnaires themselves
• Patients must be under treatment or follow-up at one of the participating hospitals.

Exclusion Criteria:

• Too ill to complete questionnaires (according to advice from (former) treating specialist)
• Patients with desmoids fibromatosis will be excluded because of the non-malignancy of the disease; and patients with gastrointestinal stromal tumours (GIST; ICD-10-GM codes C15-20, C26, C48 and C80) will be excluded.

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Radboud University Medical CenterOTHER

Vicky.Soomers@radboudumc.nl0031243618800